Royalty Pharma plc Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Royalty Pharma plc payments for repurchase of common stock for the quarter ending 2026-06-30 was $44.64M, a 84.69% decline year-over-year.
- Royalty Pharma plc payments for repurchase of common stock for the quarter ending 2026-03-31 was $50.10M, a 92.93% decline year-over-year.
- Royalty Pharma plc payments for repurchase of common stock for the quarter ending 2025-12-31 was $80.54M, a 53.09% increase year-over-year.
- Royalty Pharma plc payments for repurchase of common stock for the quarter ending 2025-09-30 was $146.49M, a 50.95% increase year-over-year.
- Royalty Pharma plc payments for repurchase of common stock for fiscal 2025 was $1.23B, a 434.46% increase from fiscal 2024.
- Royalty Pharma plc payments for repurchase of common stock for fiscal 2024 was $229.65M, a 24.65% decline from fiscal 2023.
- Royalty Pharma plc payments for repurchase of common stock for fiscal 2023 was $304.76M.
- Royalty Pharma plc payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $44.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $321.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $50.10M 10-Q · filed 2026-05-06 | $568.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $80.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.23B 10-K · filed 2026-02-11 |
| 2025-09-30 | $146.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.20B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $291.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.15B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $708.78M 10-Q · filed 2026-05-06 | $938.43M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $52.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $229.65M 10-K · filed 2026-02-11 |
| 2024-09-30 | $97.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $207.24M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $80.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $250.32M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $30.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $304.76M 10-K · filed 2026-02-11 |
| 2023-09-30 | $140.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 10-K · filed 2025-02-12 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-15 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 10-K · filed 2022-02-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2019-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $4.27M 10-K · filed 2022-02-15 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |